TITLE

Clinic Roundup

PUB. DATE
August 2011
SOURCE
BioWorld Today;8/2/2011, Vol. 22 Issue 148, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the enrollment in a Phase II/III trial of CF101, a drug for psoriasis, developed by Can-Fite BioPharma Ltd.
ACCESSION #
63875105

 

Related Articles

  • Dermatology.  // CenterWatch Weekly;4/6/2015, Vol. 19 Issue 13, p9 

    This article discusses the results of a phase II/III trial by pharmaceutical company Can-Fite BioPharma on the efficacy of the drug CF101 in patients with moderate-to-severe plaque psoriasis.

  • CLINIC ROUNDUP.  // BioWorld Today;5/25/2010, Vol. 21 Issue 100, p7 

    This section offers news briefs on clinical trials in the biopharmaceutical industry as of May 25, 2010. The Israeli Ministry of Health has given its approval for the Phase II trial of orally administered CF101 in glaucoma by Can-Fite BioPharma Ltd. The Swedish Medical Products Agency has...

  • Can-Fite BioPharma Announces Successful Results of its Phase I/II Liver Cancer Study with its CF102 Drug; the Study Achieved the Primary and secondary Endpoints.  // Biomedical Market Newsletter;1/7/2012, Vol. 21, p1 

    The article presents information on results of phase I/II clinical trials of Can-Fite BioPharma Ltd. drug candidate CF102 for the treatment of hepatocellular carcinoma (HCC). It is mentioned that the study had primarily evaluated the safety profile of long term administration of drug at three...

  • Can-Fite Announces a Promising Interim Analysis Data of Its Phase I/II Liver Cancer Study with the CF102 Drug.  // Biomedical Market Newsletter;5/16/2011, p369 

    The article focuses on the announcement of the Can-Fite BioPharma Ltd.'s promising Phase 1/2 interim analysis data regarding the CF102 drug for the treatment of liver cancer. It mentions that the analysis data showed a favorable safety profile for CF102 in the patient with liver cancer,...

  • FDA Grants Orphan Drug Status for CF102 for the Treatment of Hepatocellular Carcinoma to Can-Fite BioPharma.  // Biomedical Market Newsletter;2/28/2012, Vol. 21, p1 

    The article presents information the Orphan Drug Status granted for the drug candidate CF102 of Can-Fite BioPharma Ltd. by the U.S. Food and Drug Administration. The drug CF102 is used for prevention and treatment of liver cancer, hepatocellular carcinoma and the Phase I/II study of CF102 have...

  • Can-Fite: therapeutic approach bolstered by positive results in psoriasis trial.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p18 

    The article reports on the positive outcome of the psoriasis trial of Israel-based biopharmaceutical firm Can-Fite Biopharma Ltd. The 75-patient Phase II double-blind clinical study of the anti-TNF drug CF101 in patients with moderate to severe psoriasis resulted to efficacy upon oral...

  • New Ways to Bring Tears to Patients' Eyes. Stephenson, Michelle // Review of Ophthalmology;Nov2011, Vol. 18 Issue 11, p36 

    The article offers information on various dry-eye treatments under Phase II and III trials of the U.S. Food and Drug Administration (FDA). It states that the CF101 A3 adenosine receptor agonist from Can-Fite BioPharma Ltd. will be subjected to Phase III clinical trial to compare the efficiency...

  • CLINIC ROUNDUP.  // BioWorld Today;9/17/2009, Vol. 20 Issue 179, p9 

    The article offers news briefs related to pharmaceutical industry. Israel-based Can-Fite BioPharma completed its Phase II study on CF101 drug designed to cure psoriasis. The Seattle, Washington-based Cell Therapeutics Inc. accomplished its purpose in the Phase III study called EXTEND aimed at...

  • CAN-FITE BIOPHARMA INITIATES CF102 TRIAL FOR LIVER CANCER.  // Worldwide Biotech;May2009, Vol. 21 Issue 5, p8 

    This article reports on the plan of Can-Fite BioPharma of Israel to conduct a I/II clinical trial with CF102 for the treatment of liver cancer in 2009. Can-Fite announced that it will start enrolling patients for the clinical trial. The company will investigate the safety and efficacy of CF102...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics